Published in Am J Cardiol on March 01, 2008
Imaging the right ventricle--current state of the art. Nat Rev Cardiol (2010) 1.93
Right heart dysfunction in heart failure with preserved ejection fraction. Eur Heart J (2014) 1.90
Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation (2010) 1.73
Cardiac structure and function in heart failure with preserved ejection fraction: baseline findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist trial. Circ Heart Fail (2013) 1.40
Assessment and treatment of right ventricular failure. Nat Rev Cardiol (2013) 1.22
Cardiac structure and function and prognosis in heart failure with preserved ejection fraction: findings from the echocardiographic study of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) Trial. Circ Heart Fail (2014) 1.06
Right ventricular dysfunction following acute myocardial infarction in the absence of pulmonary hypertension in the mouse. PLoS One (2011) 1.06
Real-time evaluation of longitudinal peak systolic strain (speckle tracking measurement) in left and right ventricles of athletes. Cardiovasc Ultrasound (2009) 0.94
Do we have two hearts? New insights in right ventricular function supported by myocardial imaging echocardiography. Heart Fail Rev (2010) 0.89
Effect of imatinib as add-on therapy on echocardiographic measures of right ventricular function in patients with significant pulmonary arterial hypertension. Eur Heart J (2014) 0.85
Right ventricular function in preterm and term neonates: reference values for right ventricle areas and fractional area of change. J Am Soc Echocardiogr (2015) 0.85
Echocardiographic assessment of right ventricular function in inferior wall myocardial infarction and angiographic correlation to proximal right coronary artery stenosis. Indian Heart J (2013) 0.84
Assessment of right ventricular structure and function in mouse model of pulmonary artery constriction by transthoracic echocardiography. J Vis Exp (2014) 0.82
High prevalence of right ventricular dysfunction in ICD patients with shocks: a potential new predictor in risk stratification. J Interv Card Electrophysiol (2011) 0.80
Echocardiographic Linear Dimensions for Assessment of Right Ventricular Chamber Volume as Demonstrated by Cardiac Magnetic Resonance. J Am Soc Echocardiogr (2016) 0.79
Early echocardiographic changes after percutaneous implantation of the Edwards SAPIEN transcatheter heart valve in the pulmonary position. Echocardiography (2013) 0.79
Right ventricular myocardial performance index is decreased with severe pressure-overload cardiac hypertrophy in young rats. Pediatr Cardiol (2013) 0.77
Right side of heart failure. Heart Fail Rev (2012) 0.77
Diabetes is an independent predictor of right ventricular dysfunction post ST-elevation myocardial infarction. Cardiovasc Diabetol (2016) 0.77
How best to assess right ventricular function by echocardiography. Cardiol Young (2015) 0.76
Echocardiographic assessment of right ventricular functions in nondiabetic normotensive hemodialysis patients. Interv Med Appl Sci (2015) 0.75
Time Dependence of the Effect of Right Ventricular Dysfunction on Clinical Outcomes After Myocardial Infarction: Role of Pulmonary Hypertension. J Am Heart Assoc (2016) 0.75
Right ventricle chamber of young trained athletes: morphology and function. Asian J Sports Med (2013) 0.75
Chronic exposure to low doses of HgCl2 avoids calcium handling impairment in the right ventricle after myocardial infarction in rats. PLoS One (2014) 0.75
Echocardiographic Evaluation of Changes in Cardiac Hemodynamics and Loading Conditions after Transthoracic Minimally Invasive Device Closure of Atrial Septal Defect. PLoS One (2015) 0.75
Right heart function deteriorates in breast cancer patients undergoing anthracycline-based chemotherapy. Echo Res Pract (2016) 0.75
Right Ventricular Dysfunction Impairs Effort Tolerance Independent of Left Ventricular Function Among Patients Undergoing Exercise Stress Myocardial Perfusion Imaging. Circ Cardiovasc Imaging (2016) 0.75
Right ventricular failure predicted from right bundle branch block: cardiac magnetic resonance imaging validation. Cardiovasc Diagn Ther (2016) 0.75
Prognostic value of three-dimensional echocardiographic right ventricular ejection fraction in patients with pulmonary arterial hypertension. Oncotarget (2016) 0.75
Early Detection of Drug-Induced Renal Hemodynamic Dysfunction Using Sonographic Technology in Rats. J Vis Exp (2016) 0.75
Clinical and echocardiographic predictors of cardiorenal syndrome type I in patients with acute ischemic right ventricular dysfunction. Cardiorenal Med (2013) 0.75
The change in right ventricular systolic function according to the revascularisation method used, following acute ST -segment elevation myocardial infarction. Cardiovasc J Afr (2016) 0.75
Apical traction: a novel visual echocardiographic parameter to predict survival in patients with pulmonary hypertension. Eur Heart J Cardiovasc Imaging (2015) 0.75
Does surgically induced right bundle branch block really effect ventricular function in children after ventricular septal defect closure? Pediatr Cardiol (2014) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med (2004) 19.42
Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med (2010) 14.43
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet (2010) 14.24
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med (2009) 14.13
Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr (2010) 13.12
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med (2005) 12.46
Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med (2009) 12.44
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol (2013) 11.88
Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med (2014) 11.77
Strategies for multivessel revascularization in patients with diabetes. N Engl J Med (2012) 10.79
Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med (2003) 10.57
Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med (2012) 10.09
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 10.07
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 10.02
Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 9.98
Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA (2004) 9.74
Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med (2004) 9.67
C-reactive protein levels and outcomes after statin therapy. N Engl J Med (2005) 9.47
Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med (2012) 9.46
Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med (2004) 9.13
Coronary intervention for persistent occlusion after myocardial infarction. N Engl J Med (2006) 8.74
Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet (2009) 8.54
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet (2003) 8.12
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation (2006) 8.01
Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med (2012) 7.93
Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med (2007) 7.86
Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med (2006) 7.62
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Spironolactone for heart failure with preserved ejection fraction. N Engl J Med (2014) 7.48
Sudden death in patients with myocardial infarction and left ventricular dysfunction, heart failure, or both. N Engl J Med (2005) 6.86
Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA (2007) 6.25
Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet (2009) 6.25
Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med (2006) 6.15
A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med (2009) 5.81
A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med (2002) 5.55
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA (2012) 5.27
Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial. Lancet (2007) 5.06
Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. J Am Coll Cardiol (2007) 4.74
Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med (2013) 4.67
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med (2015) 4.56
Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med (2010) 4.52
Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD study: a randomized controlled trial. JAMA (2003) 4.44
Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA (2007) 4.30
Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation (2007) 4.11
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail (2010) 3.90
2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation (2013) 3.86
Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation (2006) 3.85
Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med (2014) 3.80
Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2003) 3.78
Red blood cell distribution width and mortality risk in a community-based prospective cohort. Arch Intern Med (2009) 3.73
Aortic diameter, wall stiffness, and wave reflection in systolic hypertension. Hypertension (2007) 3.68
Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: double-blind, randomised, controlled clinical trial. Lancet (2005) 3.67
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet (2012) 3.66
Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med (2008) 3.49
Digoxin reduces 30-day all-cause hospital admission in older patients with chronic systolic heart failure. Am J Med (2013) 3.46
Analyses of cancer data from three ezetimibe trials. N Engl J Med (2008) 3.44
Controversies in ventricular remodelling. Lancet (2006) 3.39
Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA (2004) 3.39
The amyloidogenic V122I transthyretin variant in elderly black Americans. N Engl J Med (2015) 3.36
Heart failure. Lancet (2005) 3.33
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA (2008) 3.31
Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation (2004) 3.30
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25